Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

For patients with immunoglobulin G (IgG)4-related disease, inebilizumab reduces the risk for flares and increases the ...

Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.

IgG4-related disease is a multiorgan, relapsing, fibroinflammatory, immune-mediated disorder with no approved therapy. Inebilizumab targets and depletes CD19+ B cells and may be effective for ...

Acepodia (6976:TT), a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms, ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...

An international, Phase III clinical trial led by investigators at Mass General Brigham could improve the treatment of a rare ...

Dr. Stone said, "A crucial finding for people living with IgG4-RD now has been the efficacy in disease control exerted by B cell depletion. I'm enthusiastic now not only about the possibility of ...

Discover six bispecific antibody companies developing a two-in-one approach to delivering targeted therapeutics to patients.